15/09/2025
Why Monitoring Matters – New LinkedIn Series
Too often, clinical trial monitoring is dismissed as box-ticking or an expensive regulatory obligation. But in reality, it’s the foundation that keeps a trial alive, trustworthy, and inspection-ready.
Over the next 10 weeks, I’ll share a new post every week exploring why monitoring is not a “nice-to-have” but a non-negotiable for biotech sponsors.
What we’ll cover:
1️⃣ Clinical Trial Monitoring – The Heartbeat of a Clinical Trial
2️⃣ How Monitoring Prevents Protocol Deviations
3️⃣ Would Your ISF Survive an Inspection?
4️⃣ When Queries Pile Up, Data Quality Is at Risk
5️⃣ A Disengaged Site Can Derail Your Trial
6️⃣ Continuous Site Training – Beyond the Initial Session
7️⃣ A CRA Is More Than a Box-Ticker
8️⃣ Skip the Hard Checks Early, and You’ll Pay Later
9️⃣ Studies Don’t Fail Overnight – Recognizing Early Warning Signs
🔟 Lessons Learned
These insights come directly from 25+ years of hands-on experience in clinical operations, including rescuing studies on the brink of failure.
If you’re a biotech leader preparing for your first trial — or a venture partner supporting one — this series is for you.
Follow along, share your thoughts, and let me know in the comments: What’s your biggest challenge with monitoring today?
